Biological treatment and the potential risk of adverse postoperative outcome in patients with inflammatory bowel disease: An open source expert panel review of the current literature and future perspectives

Alaa El-Hussuna

1Aalborg University Hospital Hobrovej, Aalborg

Corresponding author’s contact information:

Alaa El-Hussuna
Aalborg University Hospital
Hobrovej 22, 9000 Aalborg
Email: alaanewemail@gmail.com
Phone: +45 28 94 49 02

Open source research article: Written with, and peer reviewed by, contributors on Twitter using online shared Google document.

Funding information: None

Conflict of interests: None

Open source research collaborating group (#OpenSourceResearch): Names and Twitter accounts of the 41 contributors are provided at the end of this document

Contributors:

Alaa El-Hussuna, Pär Myrelid, Stefan D. Holubar, Paulo G. Kotze, Graham Mackenzie Gianluca Pellino, Des Winter, Justin Davies, Ionut Negoi, Perbinder Grewal, Gaetano Gallo, Kapil Sahnan, Ines Rubio-Perez, Daniel Clerc, Nicolas Demartines James Glasbey, Miguel Regueiro, Ahmed E. Sherif, Peter Neary, Francesco Pata, Mark Silverberg, Stefan Clermont, Sami A. Chadi, Sameh Emile, Nicolas Buchs, Monica Millan, Ana Minaya-Bravo, Hossam Elfeki, Veronica De Simone Mostafa Shalaby, Celestino Gutierrez, Cihan Ozen, Ali Yalçınkaya, David Rivadeneira, Alessandro Sturiale, Nuha Yassin, Antonino Spinelli, Jay Warusavitane, Argyrios Ioannidis Steven Wexner, Julio Mayol

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abbreviations

ACPGBI - The Association of Coloproctology of Great Britain and Ireland
ASCRS – American Society of Colon and Rectal Surgeons
ASA – American Society of Anesthesiology
BMI – Body Mass Index
CCF- Crohn’s & Colitis Foundation (formerly known as the Crohn’s & Colitis Foundation of America [CCFA]).
CCI - Comprehensive Complication Index
CD – Crohn’s Disease
CDAI - Crohn’s Disease Activity Index
ECCO – European Crohn’s and Colitis Organization
ESCP – European Society of ColoProctology
ELISA - Enzyme-Linked Immuno-Sorbent Assay
GRADE - Grading of Recommendations, Assessment, Development and Evaluations
HBI – Harvey Bradshaw Index
IBD – Inflammatory Bowel Disease
IL – Interleukin
IPAA – Ileal Pouch Anal Anastomosis
IV – Intravenous
LOS - Length of Stay
PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SC – Subcutaneous
SoMe4Surgery – Social Media for Surgery
TNF – Tumor Necrosis Factor
a-TNF- Anti-Tumor Necrosis Factor alpha inhibitors
UC – Ulcerative Colitis
Abstract

**Background:** There is widespread concern that treatment with biologics agents may be associated with sub-optimal postoperative outcome after surgery for inflammatory bowel diseases (IBD).

**Aim:** We aimed to search and analyse the literature regarding the potential association of biologic treatment on adverse postoperative outcome in patients with IBD. We used the subject as a case in point for surgical research. The aim was not to conduct a new systematic review.

**Method:** This is an updated narrative review written in a collaborative method by authors invited through Twitter via the following hashtags (#OpenSourceResearch and #SoMe4Surgery). The manuscript was presented as slides on Twitter to allow discussion of each section of the paper sequentially. A Google document was created which was shared across social media and comments and edits were verified by the primary author to ensure accuracy and consistency.

**Results:** Forty-one collaborators responded to the invitation, and a total of 106 studies were identified that investigated the potential association of pre-operative biological treatment on postoperative outcome in patients with IBD. Most of these studies were retrospective observational cohorts, 3 were prospective, 4 experimental and 3 population-based studies. These studies were previously analyzed in 10 systematic/narrative reviews and 14 meta-analyses. Type of biologic agents, dose, drug concentration, anti-drug antibodies, interval between last dose and types of surgery varied widely among the studies. Adjustment for confounders and bias control ranged from good to very poor. Only 10 studies reported postoperative outcome according to Clavien-Dindo classification.

**Conclusion:** Although a large number of studies investigated the potential effect of biological treatment on postoperative outcomes, many reported divergent results. There is a need for randomized controlled trials. Future studies should focus on the avoiding the weakness of prior
studies we identified. Seeking collaborators and sharing information via Twitter was integral to widening the contributors/authors and peer review for this paper, and was an effective method of collaboration.

Keywords: Inflammatory bowel disease, Crohn’s disease, ulcerative colitis, biologic treatment, biologics, anti-TNF alpha, postoperative outcome, surgery.

What does this paper add to existing literature and what it does not add? This study represents the most extensive literature review done on the subject using a unique, social media-based, methodology. It identifies all the studies published until 30th September 2018, analyses these studies, described the 106 studies and attempt to answer these questions:

1. Why these 106 studies reported divergent results?
2. Why there is a large number of studies with severe limitations in methodology? Is this not a waste of resources?
3. Can social media and internet connection improve research quality and facilitate optimal design of future studies?

To the best of our knowledge, this represents the first research project conducted using social media to recruit co-authors and paragraph-by-paragraph revision of the manuscript via the #OpenSourceResearch hashtag.

The authors would like to emphasise that:

1. This is not a systematic review or meta-analysis because there are already many systematic reviews and meta-analysis about the subject with divergent conclusions.
2. This is a case in point for surgical research. With such study, the authors hope, less temptation to conduct small series studies will be encountered and better cooperation in conducting larger scale studies will be encouraged to advance surgical science.

Introduction:
Biologic therapies have revolutionized the management of inflammatory bowel diseases (IBD), i.e. Crohn’s disease (CD) and ulcerative colitis (UC). Biologics, including anti-TNF-alpha agents (a-TNF), and more recently anti-integrin and anti-IL-12/23 agents, are reserved for patients with moderate-to-severe disease activity, or for patients who are medically-refractory to conventional therapy such as azathioprine, mercaptopurine, methotrexate or corticosteroids. However, TNF is an important component of the immune defense mechanism and plays a role in wound healing through a dose-dependent effect on angiogenesis\(^1\) and collagen synthesis\(^2\)–\(^4\). Inhibition of TNF mediated pathways may impair wound healing after surgery thus theoretically increasing the risk of postoperative complications such as surgical site infection and anastomosis-related complications, although the latter has to date never been demonstrated in any clinical study or trial.

Despite having been used since 1998, the natural history of CD appears to be unaffected using a-TNF\(^5\). Hence, the risk of surgery to treat refractory CD may not have changed in the era of biologics. The overall risk of surgery was 22% in a recent European study\(^6\) and risk for second surgery is 28.7% based on meta-analysis of population-based studies\(^7\). Furthermore, up to 50% of CD patients have been exposed to an a-TNF at time of their first surgery\(^8\). In UC, the risk of colectomy seems to have decreased in the era of biologics\(^9\). It is not clear whether this change is related to the introduction of biologics or better preoperative optimization.

To date, there are 106 scientific papers assessing the effect of a-TNF therapy on postoperative outcome, with divergent conclusions. As such there is a need to assess the current evidence, and to assess each studies strength and weakness, so as to help plan future studies with
optimal design and methodology. Thus, the aim of this study was to assess the potential association between preoperative exposure to biologics with postoperative outcomes in IBD patients, and to make recommendations for the optimal design of future studies.

Method
This study is a narrative review based on a published systematic review by one of the authors (AE). In this update, all eligible studies were included. No statistical analyses or bias control analyses were conducted because of the wide heterogeneity of the included studies. Biologic treatment was defined as treatment with a-TNF agents (e.g. infliximab or adalimumab), integrin inhibitors (e.g. vedozulimab) or IL-12/23 inhibitors (e.g. ustekinumab).

Aim
The aim of this review is to PROVID a case in point about surgical research by examining one subject in MINTIOUS details to identify the limitations of REPORTED studies and attempt to lead the design of future studies.

Eligibility Criteria
Case-control and cohort studies were included irrespective of publication status, year of publication, or language. Included studies assessed patients with CD or UC undergoing laparoscopic or open abdominopelvic surgery. Based on pharmacokinetic studies, the intervention group included patients who received any type or dose of biologics within 3 months of surgery.

Outcome Measures
Outcome measures were assessed after 30 days of follow-up. The outcomes were assessed as defined by the authors of the included studies.

Search strategy and method of updating the review
The search strategy is attached as a supplementary on-line file. The search was prospectively updated by the authors using:

1. Alerts from PubMed.gov
2. Alerts from researchgate.com (any citation of articles by authors).

3. Alerts from relevant journals

4. Attending relevant conferences (ESCP, ECCO, ACPGBI, ASCRS).

5. Following topical developments in the subject as the authors are reviewers in many international journals and are, or have been, members of guidelines committees for UC and CD with the following organization: European Crohn’s and Colitis Organization, Crohn’s and Colitis Foundation, and the American Society of Colon & Rectal Surgeons.

6. Contacting experts in the field using the Twitter #SoMe4Surgery hashtag. Many authors are expert in this subject (AH, SH, PK, PM, JD, AE, AS, NY, SW, please see the suplmentary files with list of all authors). All the contributors were asked to update the list of the included articles using their Twitter network to ensure that all relevant studies are included. Two additional papers were identified via this mechanism.

Open source research project
The paper was written in a collaborative method with authors invited personally and through Twitter via the following hashtags (#OpenSourceResearch and #SoMe4Surgery). A Google document was created which was shared across social media and comments and edits were verified by the primary author to ensure accuracy and consistency. The manuscript was presented on Twitter in sequential posts by section. Each post contained 1-2 paragraphs of the manuscript modified to fit the limited space in Twitter and include powerpoint slides and images. This collaboration allowed this research and paper to be unique in the way it was written and edited.

Twitter offered a platform to engagege researchers, to broaden the search and to conduct scientific discussions.
The final draft was sent by email to all contributors for feedback prior to submission and the primary author (AE) completed the final draft which was then edited for grammar by a native English-speaking author (SH).

Twitter analysis of the #OpenSourceResearch
Twitter is an American-based yet international online news and social networking service to which users post and interact with messages known as "tweets". Tweets were originally restricted to 140 characters, but this limit was doubled for all languages except Chinese, Japanese, and Korean. Registered users may post, like, and “retweet” tweets, but unregistered users can only read them. Users access Twitter through its website interface, through Short Message Service (SMS) or its mobile-device application software ("app").

As this paper was written as a social-media based collaboration, it was important to capture social media activity as potential source material for the paper, and to assess the response to the idea of an open source research paper, as well as to document the main influencers of these discussions. Data were collected through two tools – “Followthehashtag” for geographical mapping and gender split of tweeters, and “NodeXL” to document the networking interactions between tweeters and describe the interactions between these tweeters (replies, retweets and mentions of other tweeters). Both tools can be used to quantify the number of tweeters, retweeters, and tweets. Both tools also provide information about individual tweets. Additional information is available at http://analytics.followthehashtag.com/#/id=dashboard and at https://www.smrfoundation.org/nodexl/.

Results
We identified a total of 106 studies that investigated the impact of pre-operative biological treatment on postoperative outcome in patients with IBD. The relation of a-TNF therapy with postoperative outcomes in patients with IBD has been investigated in 32 retrospective CD cohorts\(^{11-42}\) (CD with/without UC), in 16 retrospective cohorts (UC)\(^{43-58}\) three prospective ones\(^{59-61}\), \ldots
four experimental, three population based studies, ten narrative reviews and 14 meta-analyses making a total of 82 studies over the past 15 years (Table 1-4). In addition, 27 studies investigated this relation as part of other risk factors of unfavorable postoperative outcome, as well as studies with a focus on rheumatoid arthritis (Table 5). The 54 clinical studies which included 32 retrospective cohorts of CD, 16 retrospective cohorts of UC, 3 prospective cohorts of CD and 3 nation-based studies are demonstrated in details in Tables 1-3. In total these clinical studies have included 22,923 patients of whom 5,501 (24%) were on pre-operative biological treatment.

How confounding factors were addressed in the different studies? The included studies varied in the method in which they addressed potential confounding factors as type of medication, time internal between medication and surgery, drug concentration, presence of anti-drug antibodies. Here is an account of these confounding factors and how they were addressed in different studies.

**Type of medication**

Some studies defined the type of biological treatments (e.g. Infliximab); others reported a broad category of treatment (e.g. a-TNF, including certolizumab pegol and golimumab) while a few studies included all biological treatments without any definition (Tables 1-3). This may influence the results as these agents differ in their efficacy, half-life, mechanism of action, pharmacodynamics and pharmacokinetics including bioavailability and elimination/excretion (in stool for example). Infliximab, for instance, is administered intravenously (IV), while adalimumab, certolizumab pegol, and golimumab are administered subcutaneously (SC). Intravenous administration is associated with large volume, rapid central distribution with low variability in bioavailability. Absorption from SC administration is slow, and it may induce more immunogenicity. The IBDRSponse trial has drawn attention to this problem and challenged the results obtained from previous studies where a mix of biological treatment agents were registered.
**Time interval between medication and surgical intervention**

Most of the studies chose a 8-12 week interval from the last dose of a-TNF to the date of surgical surgery (Tables 1-3). This is mainly based on pharmacokinetics of infliximab (the most commonly used drug), assuming 1\textsuperscript{st} order elimination kinetics (Figure 1) which may or may not be applicable; of note trace levels of infliximab can be found up to 12 weeks after administration\textsuperscript{90}. However, during this time, drug concentration and its efficacy can vary from a peak at the time of administration to a trace level at the end of time interval (see the next section).

**Drug concentration in the peripheral blood (serum levels of biological agents)**

Drug concentration in the peripheral blood correlates with drug concentration in the inflamed tissue\textsuperscript{91} and it varies during the 12-week period prior to surgery with a peak at the time of administration and a fading to trace levels in the following weeks (Figure 1). Drug concentration is essential for drug action and for the stimulation of anti-drug antibody formation\textsuperscript{90}. Reporting biologic treatment at 12 weeks interval can therefore be misleading and interpretation of the results may differ. Only 4 studies investigated drug concentration in the peripheral blood\textsuperscript{29,30,60,61}. These 4 studies reported the drug concentration at different time intervals using trough levels in the serum. These trough levels are measured by using enzyme-linked immunosorbent assay (ELISA) and these levels may be decreased by leakage of the antibodies through inflamed bowel mucosa into the stool\textsuperscript{92} and/or deactivation by development of antibodies against the injected anti-TNF (anti-drug antibodies)\textsuperscript{93}. Fumery \textit{et al}\textsuperscript{60} reported drug concentration of 76 of the 93 patients who received a-TNF treatment within a period of 12 weeks before surgery. The measurement of trough level was done on the day of surgery\textsuperscript{60}. Lau \textit{et al}. reported serum drug concentrations from samples drawn at varying pre-operative time points in 143 patients with IBD treated with a-TNF\textsuperscript{30}.

Waterman \textit{et al}. reported drug concentration in a subset of 19 patients with UC exposed to a-TNF treatment within 8 weeks prior to surgery. The authors also reported anti-drug antibodies\textsuperscript{29}.

Waterman \textit{et al}. analysis included patients exposed to a-TNF treatment within 180 days of surgery.
El-Hussuna\textsuperscript{61} \textit{et al} reported in IBDResponse study drug concentration and anti-drug antibodies for 18 patients with IBD. Samples were collected within 24 hours before surgery as well as 6, 24 and 48 hours after surgery providing a unique chance to examine the drug and anti-drug antibodies in this group of patients.

\textit{Anti-drug antibodies}

The IBDResponse trial\textsuperscript{61} showed that some patients develop anti-drug antibodies to a-TNF agents regardless of the route of administration (IV or SC). These anti-drug antibodies may reduce the efficacy of drugs. Misinterpretation of results in the studies where these antibodies were not measured cannot be dismissed. Only two studies\textsuperscript{29,61} measured and reported these anti-drug antibodies. Concurrent administration of immunomodulators has been shown to reduce the formation of anti-drug antibodies\textsuperscript{90}.

How the included studies adjusted for potential confounding factors in multi-variate anlysis

Many researchers suspected confounding factors play a role and affect postoperative outcomes. These factors have a varying degree of influence on the postoperative outcome and with increasing influence by the number of concurrent risk factors. Some of these factors are well-studied such as concurrent medications, while others are less studied such as pre-operative optimization, the latter which has been recently shown to have a strong influence on the postoperative outcome\textsuperscript{94,95}. Three categories of confounding factors can be identified and have been studied:

\textit{Factors with questionable impact as shown by the studies that adjusted for these factors:}

a) Type of surgical intervention and access to abdominal cavity (studies of ileo-caecal resection\textsuperscript{15,19,34,60,96}, studies of different types of bowel resections with or without stricturoplasty\textsuperscript{11–14,16–18,22–25,27–33,36–40,42,59,66,97} and studies of ileostomy reversal\textsuperscript{26}. In patients with UC most of the studies reported postoperative outcome after subtotal colectomy\textsuperscript{36,43–46,48,55,67,68}, completion proctectomy\textsuperscript{57}, ileal pouch-anal anastomosis (IPAA)\textsuperscript{43–45,48,50,51,53,54,58,98} and other procedures in addition to the above-mentioned\textsuperscript{49}.
b) One third of studies adjusted for BMI\textsuperscript{15,16,19,24,28,29,32,33,36,38–40,43,45,49,53,54,58–60,96}.

c) Many studies adjusted for ASA score\textsuperscript{14,15,33,34,36,38,45,54,59,96}. However, many studies reported comorbidity,\textsuperscript{19,26–28,32,33,36,40,45,48,53,54,67} but few used Charlson comorbidity score\textsuperscript{16,25,66,68}.

d) Previous intestinal resections reported/adjusted for in 14 studies\textsuperscript{12,14–16,19,23,27,28,36,39,40,60,96,99}.

e) Disease phenotype reported was reported in many studies\textsuperscript{13–19,22,29,30,34,36,38,39,59,60,97,99}.

f) The affected bowel segment/length or disease location was reported in 20 studies\textsuperscript{12–16,19,27,29,36,39,44–46,50,58–60,96,97,99}.

g) Duration of operation was reported in some studies\textsuperscript{15,23,28,36,40,53,59,9642}.

h) Preoperative intra-abdominal sepsis (intra-abdominal abscess and/or enteric fistula) was reported in nine studies\textsuperscript{13,15,16,30,34,59,60,9642}.

i) Disease duration was reported in 15 studies\textsuperscript{12,16,18,22,27,28,35,36,38,39,46,58,66,67,99}.

j) Urgency of surgical intervention was reported in one third of studies\textsuperscript{12,14–18,25,27,29,31,33,35–38,40,45,48,50,54,59,60,68,96,97,942}. Some studies excluded urgent/emergency operations to attain a homogenous group of elective surgical procedures\textsuperscript{28,38,61}.

k) Surgeon’s experience (trainee, general surgeon, or colorectal surgeon) was reported in only three studies\textsuperscript{30,31,96}.

l) The type/configuration of anastomosis or stoma construction was reported in several studies\textsuperscript{14,15,19,33,45,50,54,59,96}. One study included stricturoplasty in addition to primary anastomosis\textsuperscript{14}. Patients who received a diverting stoma were excluded in some studies\textsuperscript{38,42} while other studies investigated these patients in sub-group analyses\textsuperscript{59}.
m) Other factors like intra-operative blood loss\textsuperscript{37,42}, indication for surgery\textsuperscript{12,23,25,27,29,30,34,40,50}, multi-centre versus single centre\textsuperscript{27–30,32,33,35,39,42,54,442}, leucocytosis\textsuperscript{100} were reported but they appear to have minimum or no effect on the postoperative outcome. Close cooperation between surgeon and gastroenterologist in pre-surgical decision making may have an impact on postoperative outcome\textsuperscript{25,101} but this factor is difficult to measure and not reported.

\textit{Factors expected to have large impact but were less-well studied}

a) Pre-operative optimization: few studies reported interventions to optimize the patients prior to surgery e.g. nutritional support\textsuperscript{15,59,60,96}, correction of anemia, or prehabilitation.

b) Use of a mechanical bowel preparation, which has been associated with anastomotic leaks rates, was reported in only one study.\textsuperscript{15}

\textit{Factors which would be expected to have a large impact on postoperative outcome}

a) Concurrent medication was reported by almost all studies\textsuperscript{11–15,17–19,22–25,27–40,43–46,48–51,53–55,58–60,66,67,96–98} except one population-based study on UC.\textsuperscript{68}

b) Although nutritional status is widely known to influence postoperative outcomes,\textsuperscript{95,102} it was only reported in some studies while others did not report it\textsuperscript{60,66,52,496,19}. Nutritional status was measured indirectly by assessment of serum albumin and/or haemoglobin\textsuperscript{11,16,18,24,25,27,29,30,32,33,35–37,39,40,45,49,50,55,59,60,96–98} in those studies that adjusted for nutritional status. The IBDResponse trial\textsuperscript{61} used a validated standard score (nutritional risk screening which included weight loss more 10% of body weight) to assess nutritional status.

c) Smoking is well-documented risk factor of surgical site infection\textsuperscript{95} however, with small sample size series (as in case of most studies) is it difficult to demonstrate statistical significance due to lack of power. Data on smoking was reported by some studies\textsuperscript{11,13–16,18,19,24,28,30,32–36,46,49,50,55,58–60,68,96,97}.
d) Crohn’s disease activity index (CDAI) was reported in two studies only\textsuperscript{60,99} while Harvey-Bradshaw index (HBI) was reported in one study\textsuperscript{61}. One study reported ACG severity of disease index\textsuperscript{38} while another one applied a local classification of disease activity\textsuperscript{28}. In UC studies, one study used deprivation index\textsuperscript{68}, while others used a local disease activity index\textsuperscript{36,48} or the Mayo score\textsuperscript{55}. Regarding disease severity, there is a high likelihood that the most severely ill patients received anti-TNF, while the less ill patients did not. One study tried to compare similar groups where all patients received anti-TNF at any time during the disease course\textsuperscript{14}, either at time of surgery or prior to (but withheld) vs. after surgery.

**How the included studies reported outcomes**

Different methods were used to report the postoperative outcome making the comparison of studies difficult. Some studies reported major and minor complications\textsuperscript{16,19,22,23,37,39}. Others reported short-term (early) and long-term (late) postoperative morbidity\textsuperscript{12,23,28} A third category of studies reported septic/infectious\textsuperscript{11,12,14,17,19,27,31,32,35,40,43,46,54,58,59,99} and non-septic/non-infectious complications. A few studies used the classification of surgical versus medical complications\textsuperscript{18,30,44,97} while other studies presented postoperative complications without classification or grading.\textsuperscript{14,16,24,25,27,29,33,34,49,51,60,66,67,98} However, there was increasing tendency to report outcomes according to Clavien-Dindo classification of postoperative complications\textsuperscript{14,19,28,30,53,59,60,96,97}. One study reported outcome when biological treatment was used after surgical intervention in CD\textsuperscript{99}.

To the best of our knowledge, one study has used the Comprehensive Complications Index, a relatively new composite outcome of any complication weighted by Clavien-Dindo level\textsuperscript{60}. Interestingly, no difference in the length of stay (LOS) postoperatively was shown between patients treated with biological agents and those who did not receive treatment in the studies where LOS was reported. This was unexpected in studies that reported increased complication rates in patients treated with biological agents, as LOS will be longer in patients with postoperative complications.
How the different studies conducted statistical analyses
Most of the statistical analyses were done in similar fashion \textit{i.e.} univariate analyses with $\chi^2$,
Student’s t-test, or Fisher’s exact tests for categorical and Mann-Whitney, Wilcoxon signed-rank
tests for continuous variables. However, regarding multivariable analyses, many studies did not
report what variables were entered in multivariate analyses, nor how these variables were chosen
for the multivariate analyses\textsuperscript{23,38}. Errors in interpretation of statistical results were not uncommon
for instance lack of adjustment for confounding factors\textsuperscript{26,37}.

Discussion
Despite the large number of studies available in the literature, the relationship between biologic
treatment and postoperative outcome in IBD is still controversial. During the last 15 years there
have been improvements in study design, statistical analyses and sample size; moving from high-
risk of bias studies\textsuperscript{37} to more recently low-risk of bias studies\textsuperscript{59}; nevertheless the topical debate and
controversy continues. There are three layers of complexity that made it difficult to reach definitive
conclusions about the issue at hand:

1. **Difficulty of conducting clinical research** compared to basic science research. Clinical
research is becoming more difficult due to the increased complexity of regulations and
governance which can be far from patients’ interests\textsuperscript{103}. Up to half of the approved studies by
ethics committees are never published\textsuperscript{104}. It is well documented that clinical research attracts
much less funding than basic science or translational research adding another challenge for
outcomes research\textsuperscript{105}.

2. **Difficulty in conducting research in surgery compared to medical specialties.** Variation in
surgical practice affects postoperative outcome and leads to a strong confounding factor in
surgical research. Few studies include surgeon experience or years from training.
3. Difficulty in conducting IBD research. There is no doubt IBD is complex and heterogeneous; the treatment is complex as are the pre-operative and postoperative assessments. To this end, a number of groups have been working towards developed standardized outcome sets to facilitate comparison of data and effective meta-analysis. Moreover, investigator-initiated trials often fail due to insufficient enrollment of patients with IBD, and a priori power analyses are rarely reported. Only one third to half of patients with IBD need surgery during their lifetime (75% in CD) making it even harder to recruit patients. Funding is a general problem in research, but it is more prominent in investigator-initiated trials, especially in IBD. Having said this, it might be assumed that research in IBD surgery is very well planned to reduce poor quality and ensure best use of resources. However, as of today this is not the case which as this review demonstrates. Large amount of resources were used in repeating studies with minor variations in design.

Crohn’s Disease
According to recently published guidelines, surgery in patients with receiving a-TNF therapy may be associated with an increased risk of complications. Chronologically, the American Society of Colon and Rectal Surgeons (ASCRS) 2015 clinical practice guideline on CD stated that patient receiving pre-operative biologic treatment (i.e. a-TNF or cyclosporine) should be considered for staged procedures because of postoperative complications risk. The authors suggested final decision should be up to surgeon discretion using an individualized approach to each patient. A delay of at least 8 weeks was proposed for elective whenever possible. The recommendations were graded as weak, quality of evidence 2C.

The European Crohn’s and Colitis Organization (ECCO) published its third evidence-based CD consensus in 2016, where the impact of biologic treatment for patients undergoing surgery was deemed unclear and controversial. The authors based their statement on controversial data and
advocated optimal pre-operative preparation. A joint statement of the ESCP and ECCO considered a-TNF to be associated with risk of postoperative complications, particularly sepsis (surgical site infections, abdominal abscesses, anastomotic leaks) and higher readmissions\textsuperscript{112}. Nevertheless, no recommendation was made regarding the interval of biological treatment withdrawal. All guidelines agree on the higher risk associated with long-term steroid therapy. Prednisolone 20 mg daily or higher for > 6 weeks was associated with higher postoperative surgical complications, especially when used in combination with biologic treatment\textsuperscript{110-112}. The American Gastroenterological Association (AGA) did not published specific recommendation on the clinical management of biological treatment prior to surgery.

\textit{Ulcerative colitis}

Published guidelines on the surgical management of UC includes the ECCO consensus\textsuperscript{113}. For acute situations, performing staged procedures (i.e. sub-total colectomy with end ileostomy as first stage) was advised for patients receiving biologic treatment (a-TNF) and/or Prednisolone 20 mg daily or higher for > 6 weeks. Regarding pre-operative management of biologic treatments, the increased risks of postoperative complications, although controversial, were outlined, and single stage proctocolectomy with ileo-anal pouch reconstruction, for patients under a-TNF therapy, was not recommended\textsuperscript{113}. Guidelines from the ASCRS published in 2014\textsuperscript{114} lacked definitive consensus statement on the management of a-TNF prior to elective surgery for UC. According to the authors, literature was insufficient to assess the impact of biological treatment on postoperative outcomes and there was a claim for multi-institutional larger studies.

There is no statistical model to predict the effect of various confounding factors on the postoperative outcomes in patients with IBD. It is nevertheless believed that the weight of these confounding factors in the final model is certainly different, and no standard recommendations for which variables
to include in a multivariate model exists, thus there is wide heterogeneity in model building, thus leading to varying and potentially non-comparable results and conclusions. Going forward, propensity-score matching or inclusion of the propensity score in the multivariate model, and other novel methods such as the difference-in-difference and use of instrumental variables all may play a role in reducing both the measured, and unmeasured, bias and confounding in these studies.

**Future perspectives**

ESCP conducted a snapshot audit in 2015 in which patients with CD undergoing ileo-caecal resection and right side colectomy where included, but this snapshot study did not provide a definitive answer regarding the effect of biologic treatment on postoperative outcomes [101]. Clearly, there is a need for randomized controlled trials investigating the effect of biological treatment on postoperative outcome in patients with IBD. The Pre-operative Continuation versus Discontinuation of anti-TNF treatment in Patients with Crohn’s Disease (PCDantiPCD) trial protocol was presented in the 16th Nordic postgraduate course in colorectal surgery and at the ESCP 2018 trial session, and integrates many of the points discussed above.

Measurement of drug concentration, anti-drug antibodies and application of a standardized validated scoring systems for disease activity, nutritional status and smoking will lead to better understanding of the effect/weight of different covariates in a model that describes how anti-TNF treatment influence the postoperative outcome. Meta-analysis of these RCT will provide a solid evidence to eliminate the uncertainty of previous observational studies.

**Limitations**

This narrative updated review has the limitations of the studies included. It was not planned as a new systematic review nor meta-analysis, therefore no statistical analysis was done.
Conclusion
Many studies have investigated the effect of biologic treatment on postoperative outcome using different methodological approaches (retrospective, prospective, population-based, experimental, snapshot audit and meta-analyses) with divergent results. Future studies should focus on the avoiding the above highlighted weakness of the studies we reviewed. Consensus guidelines by the invested societies, such as ECCO, CCF and ESCP are needed to guide future research. There is also a need for a randomized controlled trial to define the association, or lack thereof, between biological and adverse postoperative outcomes.
References

1. Behm B, Babilas P, Landthaler M, Schreml S. Cytokines, chemokines and growth factors in wound healing. J Eur Acad Dermatology Venereol. 2012;26(7):812–20.

2. Lin E, Lowry SF. Inflammatory cytokines in major surgery: a functional perspective. Intensive Care Med. 1999 Mar;25(3):255–7.

3. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg. 2004 May;187(5A):11S–16S.

4. Tsirogianni AK, Moutsopoulos NM, Moutsopoulos HM. Wound healing: Immunological aspects. Injury. 2006;37(1):S5–12.

5. Peyrin-Biroulet. Surgery in a population-based cohort of crohn’s disease from Olmsted county 1970-2004. AM J Gastroentrol. 2012;13(9):1133–45.

6. Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018;gutjnl-2017-315568.

7. Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, et al. Cumulative Incidence of Second Intestinal Resection in Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. Am J Gastroentrol. 2014;109(11):1739–48.

8. Peyrin-Biroulet L, Oussalah A, Willnet N, Pillot C, Bresler L, Bigard M-A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011 Jul;60(7):930–6.

9. Colombel J. Management of Crohn’s disease of the ileoanal pouch with infliximab. Am J Gastroentrol. 2003 Oct;98(10):2239–44.

10. El-Hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL, Olaisson G, et al. The Effect of Anti-Tumor Necrosis Factor Alpha Agents on Postoperative Anastomotic Complications in Crohn’s Disease. Dis Colon Rectum. 2013 Dec;56(12):1423–33.

11. Tay GS, Bimoh DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn’s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003 Oct;134(4):565–72.

12. Colombel JF, Loftus E V, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroentrol. 2004 May;99(5):878–83.

13. White EC, Melmed GY, Vasiliauskas E, Dubinsky M, Ippoliti A, McGovern D, et al. Does Preoperative Immunosuppression Influence Unplanned Hospital Readmission After Surgery in Patients With Crohn’s Disease? Dis Colon Rectum. 2012;55(5):563–8.

14. Myrelid P, Marti-Gallostra M, Ashraf S, Sunde ML, Tholin M, Oresland T, et al. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 2014 Apr;101(5):539–45.

15. Serradori T, Germain a, Scherrer ML, Ayav C, Perez M, Romain B, et al. The effect of
immune therapy on surgical site infection following Crohn’s Disease resection. Br J Surg. 2013 Jul;100(8):1089–93.

16. Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013 Apr;108(4):583–93.

17. Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB, et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn’s disease. J Clin Gastroenterol. 2013 Jul;47(6):491–5.

18. Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, et al. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn’s Disease. Dig Dis Sci. 2017;62(2):456–64.

19. Jouvin I, Lefevre JH, Creavin B, Pitel S, Chafai N, Tirtel E, et al. Postoperative Morbidity Risks Following Ileocolic Resection for Crohn’s Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients. Inflamm Bowel Dis. 2018;24(2):422–32.

20. Kotze PG, Ludvig JC, Teixeira F V, Malluta EF, Miranda EF, Hardt MR, et al. Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s disease patients. Digestion. 2015;91(2):158–63.

21. Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, et al. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol. 2018;1(3):115–23.

22. Zimmerman LA, Saites CG, Bairdain S, Lien C, Zurakowski D, Shamberger RC, et al. Postoperative complications in children with Crohn disease treated with infliximab. J Pediatr Gastroenterol Nutr. 2016;63(3):352–6.

23. Marchal L, D’Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther. 2004 Apr 1;19(7):749–54.

24. Lightner AL, McKenna NP, Tse CS, Hyman N, Smith R, Ovsepyan G, et al. Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn’s Disease. J Crohn’s Colitis. 2017;(April):402–7.

25. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008 Oct;12(10):1730-6; discussion 1736-7.

26. Regadas FSP, Pinto R a, Murad-Regadas SM, Canedo J a, Leal M, Nogueras JJ, et al. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal. Colorectal Dis. 2011 May;13(5):555–60.

27. Rizzo G, Armuzzi A, Pugliese D, Verbo A, Papa A, Mattana C, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis. 2011 Nov;26(11):1435–44.
28. Krane MK, Allaix ME, Zoccali M, Umanskiy K, Rubin M, a, Villa A, et al. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. Dis Colon Rectum. 2013 Apr;56(4):449–57.

29. Waterman M, Xu W, Dinani A, Steinhart a H, Croitoru K, Nguyen GC, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut. 2013 Mar;62(3):387–94.

30. Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, et al. The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. Ann Surg. 2015;261(3):487–96.

31. Alsaleh A, Gaidos JKJ, Kang L, Kuemmerle JF. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2016;61(9):2602–7.

32. Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, et al. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease. J Crohns Colitis. 2017 Feb;11(2):185–90.

33. Shwaartz C, Fields AC, Sobrero M, Cohen BD, Divino CM. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. J Gastrointest Surg. 2016;20(9):1636–42.

34. Appau K a, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008 Oct;12(10):1738–44.

35. Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, et al. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017;112(9):1423–9.

36. Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, et al. Risk factors for surgical site infection and association with infliximab administration during surgery for Crohn’s disease. Dis Colon Rectum. 2013 Oct;56(10):1156–65.

37. Indar A a, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn’s disease patients. World J Surg. 2009 May;33(5):1049–52.

38. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010 Dec;14(12):1859–65; discussion 1865-6.

39. Kasparek MS, Bruckmeier A, Beigel F, Müller MH, Brand S, Mansmann U, et al. Infliximab does not affect postoperative complication rates in Crohn’s patients undergoing abdominal surgery. Inflamm Bowel Dis. 2012 Jul;18(7):1207–13.

40. Canedo J, Lee S-H, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn’s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis. 2011 Nov;13(11):1294–8.

41. Regueiro M, El-Hachem S, Kip KE, Schraut W, Baidoo L, Watson A, et al. Postoperative
infliximab is not associated with an increase in adverse events in Crohn’s disease. Dig Dis Sci. 2011 Dec;56(12):3610–5.

42. El-Hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 2012 Jun;47(6):662–8.

43. Selvasekar CR, Cima RR, Larson DW, Dozois EI, Harrington JR, Harmsen WS, et al. Effect of infliximab in short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May;204(5):956-62; discussion 962-3.

44. Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas E a, Papadakis K a, Mei L, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007 Nov;50(11):1747–53.

45. Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-?? therapy. Dis Colon Rectum. 2013;56(11):1243–52.

46. Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):14–20.

47. Zittan E, Milgrom R, Ma GW, Wong-Chong N, O’Connor B, McLeod RS, et al. Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications after Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2016 Oct;22(10):2442–7.

48. Kulaylat ASAN, Kulaylat ASAN, Schaefer EW, Tinsley A, Williams E, Koltun W, et al. Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. JAMA Surg. 2017;152(8):e171538.

49. Lightner AL, McKenna NP, Moncrief S, Pemberton JH, Raffals LE, Mathis KL. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2017;0(0):1.

50. Ferrante M, van Overstraeten A de B, Schils N, Moens A, van Assche G, Wolthuis A, et al. Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohn’s Colitis. 2017;11(11):1353–61.

51. Mor IJ, Vogel JD, da Luz Moreira a, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008 Aug;51(8):1202-7; discussion 1207-10.

52. Ferrante M, D’Hoore a, Vermeire S, Declerck S, Noman M, Van Assche G, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009 Jul;15(7):1062–70.

53. Coquet-Reinier B, Berdah S V., Grimaud J-C, Birnbaum D, Cougard P-A, Barthet M, et al.
Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch–anal anastomosis: a case-matched study. Surg Endosc. 2010;24(8):1866–71.

54. Gainsbury ML, Chu DI, Howard LA, Coukos JA, Farraye FA, Stucchi AF, et al. Preoperative Infliximab is not Associated with an Increased Risk of Short-Term Postoperative Complications After Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis. J Gastrointest Surg. 2011;15(3):397–403.

55. Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohn’s Colitis. 2012;6(3):281–6.

56. Jones GR, Kennedy N a, Lees CW, Arnott ID, Satsangi J. Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn’s disease maintenance–progress and prospects. Aliment Pharmacol Ther. 2014 Jun;39(11):1253–65.

57. Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, et al. Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Colorectal Dis. 2013;28(9):1295–306.

58. Eshuis EJ, Al Saady RL, Stokkers PCF, Ponsioen CY, Tanis PJ, Bemelman WA. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohn’s Colitis. 2013;7(2):142–9.

59. Brouquet A, Maggiori L, Zerbib P, Lefevre JH, Denost Q, Germain A, et al. Anti-TNF Therapy Is Associated with an Increased Risk of Postoperative Morbidity after Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort. Ann Surg. 2016 Feb;267(2):221–8.

60. Fumery M, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet J-M, Boschetti G, et al. Postoperative Complications after Ileocecal Resection in Crohn’s Disease: A Prospective Study From the REMIND Group. Am J Gastroenterol. 2017;112541(2):337–45.

61. El-Hussuna A, Qvist N, Zangenberg MS, Langkilde A, Siersma V, Hjort S, Gøgenur I. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: A prospective multi-center pilot study. BMC Surg. 2018; 18:91. doi: 10.1186/s12893-018-0425-0.

62. Ploug T, Andersen K, Hansen K, Hjelmborg J, Qvist N. Influence of adalimumab treatment on anastomotic strength, degree of inflammation, and collagen formation: an experimental study on the small intestine of rabbits. Inflamm Bowel Dis. 2013;19(2):254–8.

63. Strebel K, Nielsen SRH, Biagini M, Qvist N. Effect of Humira® on Intestinal Anastomotic Response in Rabbits. J Investig Surg Off J Acad Surg Res. 2015;28(3):167–72.

64. Myrelid P, Salim SY, Darby T, Almer S, Melgar S, Andersson P, et al. Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis. Scand J Gastroenterol. 2015;50(8):991–1001.

65. Ågren MS, Andersen TL, Andersen L, Schiødt CB, Surve V, Andreassen TT, et al. Nonselective matrix metalloproteinase but not tumor necrosis factor-α inhibition effectively preserves the early critical colon anastomotic integrity. Int J Colorectal Dis. 2011;26(3):329–37.
66. Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OBS, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn’s disease—a nationwide cohort study. Aliment Pharmacol Ther. 2013 Jan;37(2):214–24.

67. Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OBS, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis— a nationwide cohort study. Aliment Pharmacol Ther. 2012 Jun;35(11):1301–9.

68. Ward ST, Mytton J, Henderson L, Amin V, Tanner JR, Evison F, et al. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study. Color Dis. 2017;416–23.

69. Subramanian V, Pollok RCG, Kang J-Y, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006 Jul;93(7):793–9.

70. Ali T, Yun L, Rubin DT. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21;18(3):197–204.

71. El-Hussuna A, Theede K, Olaison G. Increased risk of post-operative complications in patients with Crohn’s disease treated with anti-tumour necrosis factor α agents—a systematic review. Dan Med J. 2014 Dec;61(12):1–6.

72. Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Papalois A, et al. The Impact of Peri-operative Anti-TNF Treatment on Anastomosis-Related Complications in Crohn’s Disease Patients. A Critical Review. J Gastrointest Surg. 2014;18(6):1216–24.

73. Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-tumor necrosis factor-α antibody therapy management before and after intestinal surgery for inflammatory bowel disease: A CCFA position paper. Inflamm Bowel Dis. 2015;21(11):2658–72.

74. Alexakis C. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg. 2015;7(12):360.

75. Chang ML, Cohen BL, Greenstein AJ. A Review of the Impact of Biologics on Surgical Complications in Crohn’s Disease. Inflamm Bowel Dis. 2015;(March):1.

76. Kotze PG, Ghosh S, Bemelman WA, Panaccione R. Preoperative use of anti-tumor necrosis factor therapy in Crohn’s disease: promises and pitfalls. Intest Res. 2017;15(2):160–5.

77. Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-Lessons from real-world experience; A systematic review and pooled analysis. Vol. 12, Journal of Crohn’s and Colitis. 2018. p. 245–57.

78. Saab M, Saab B, Olanderski M, Coy CSR, Kotze PG. Impacto dos anti-TNF nas complicações pós-operatórias na doença de Crohn: Uma revisão. J Coloproctology. 2015;35(2):128–36.

79. Yang Z-PP, Hong L, Wu Q, Wu K-CC, Fan D-MM. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg. 2014 Jan;12(3):224–30.
80. Xu 2018 Meta-analysis the influence of infliximab use on postop complications in CD.pdf.
81. Yung DE, Horesh N, Lightner AL, Ben-Horin S, Eliakim R, Koulaouzidis A, et al. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 May 17;
82. Ehteshami-Afsar S, Nikfar S, Rezaie A, Abdollahi M. systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci. 2011;
83. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012 Dec;18(12):2404–13.
84. Billioud V, Ford AC, Tedesco E Del, Colombel J-F, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. J Crohns Colitis. 2013 Mar 19;
85. Narula N, Charlton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Jun;37(11):1057–64.
86. Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn’s disease in patients undergoing abdominal surgery: A systematic review and meta-analysis. J Crohns Colitis. 2013 Mar 2;
87. Ali UA, Martin ST, Rao AD, Kiran RP. Impact of Preoperative Immunosuppressive Agents on Postoperative Outcomes in Crohn’s Disease. Dis Colon Rectum. 2014;57(5):663–74.
88. Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg. 2016;8(3):274.
89. Law CCY, Narula A, Lightner AL, McKenna NP, Colombel J-F, Narula N. Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. J Crohn’s Colitis. 2018 May 17;12(5):538–45.
90. Casteele N Vande, Gils A. Pharmacokinetics of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Adding Value to Current Practice. 2015;(May 2014).
91. Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, et al. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017;23(12):1.
92. Brandse JF, Van Den Brink GR, Wildenberg ME, Van Der Kleij D, Rispen S, Jansen JM, et al. Loss of infliximab with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–355.e2.
93. Gorovits B, Baltrukonis DJ, Bhattacharya I, Bircher MA, Finco D, Sikkema D, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol. 2018;192(3):348–65.
94. El-Hussuna A, Iesalnieks I, Horesh N, Hadi S, Dreznik Y, Zmora O. The effect of pre-
operative optimization on post-operative outcome in Crohn’s disease resections. Int J Colorectal Dis. 2017;32(1):49–56.

95. Zangenberg MS, Horesh N, Kopylov U, El-Hussuna A. Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review. Vol. 32, International Journal of Colorectal Disease. 2017. p. 1663–76.

96. 2015 European Society of Coloproctology collaborating group. The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit. Color Dis. 2017 Mar 6;

97. Kotze PG, Magro DO, Martinez CAR, Saab B, Saab MP, Pinheiro LV, et al. Adalimumab and postoperative complications of elective intestinal resections in Crohn’s disease: a propensity score case-matched study. Color Dis. 2018 Oct 20;20(3):211–8.

98. Kennedy R, Potter DD, Moir C, Zarroug AE, Faubion W, Tung J. Pediatric chronic ulcerative colitis: Does infliximab increase post-ileal pouch anal anastomosis complications? J Pediatr Surg. 2012;47(1):199–203.

99. Regueiro M, Kevin SE, Wolfgang EK, Barrie A, Pesci M, Binion D. Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn’s Disease. 2011;3610–5.

100. Galata C, Weiss C, Hardt J, Seyfried S, Post S, Kienle P, et al. Risk factors for early postoperative complications and length of hospital stay in ileocecal resection and right hemicolectomy for Crohn’s disease: a single-center experience. Int J Colorectal Dis. 2018;33(7).

101. 2015 European Society of Coloproctology collaborating group. Risk factors for unfavourable postoperative outcome in patients with Crohn’s disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO. Color Dis. 2018 Mar 15;20(3):219–27.

102. El-Hussuna A, Iesalnieks I, Horesh N, Hadi S, Dreznik Y, Zmora O. The effect of pre-operative optimization on post-operative outcome in Crohn’s disease resections. Int J Colorectal Dis. 2017 Jan 26;32(1):49–56.

103. Salman RA, Beller E, Kagan J, Hemminki E, Robert S, Savulescu J, et al. NIH Public Access regulation and management. Lancet. 2014;383(9912):176–85.

104. Blümle A, Meerpohl JJ, Schumacher M, Von Elm E. Fate of clinical research studies after ethical approval - follow-up of study protocols until publication. PLoS One. 2014;9(2).

105. Rygård SL, Kjær MN, Perner A. Statens investering i kliniske forsøg. Ugeskr Laeger. 2018;2–4.

106. Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, et al. Developing a Standard Set of Patient-Centred Outcomes for inflammatory Bowel Disease-an international, cross-disciplinary consensus. J Crohn’s Colitis. 2018 Mar 28;12(4):408–18.

107. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, et al. A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials. Clin Gastroenterol Hepatol. 2017 May;16(5):637–647.e13.
108. Schlessinger DI, Iyengar S, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, et al. Development of a core outcome set for clinical trials in basal cell carcinoma: Study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2017 Jun 9;18(1):e016146.

109. Sahnan K, Tozer PJ, Adegbola SO, Lee MJ, Heywood N, McNair AGK, et al. Developing a core outcome set for fistulating perianal Crohn’s disease. Gut. 2018 Feb 3;gutjnl-2017-315503.

110. Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, et al. Clinical practice guideline for the surgical management of Crohn’s disease. Vol. 58. Diseases of the Colon and Rectum. 2015. p. 1021–36.

111. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis. 2016 Feb;11(2):135–49.

112. Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, et al. ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohn’s Colitis. 2018 May 11;12(1):1–16.

113. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017 Jun 1;11(6):649–70.

114. Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014 Jan;57(1):5–22.

115. Claxton K, Griffin S, Koffijberg H, McKenna C. How to estimate the health benefits of additional research and changing clinical practice. Bmj. 2015;h5987.

116. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: Pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010;31(4):486–92.

117. Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn’s disease: A systematic review and meta-analysis. Int J Surg. 2014;12(3):224–30.

118. Law CCY, Narula A, Lightner AL, McKenna NP, Colombel JF, Narula N. Systematic review and meta-analysis: Preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. J Crohn’s Colitis. 2018;12(5):538–45.

119. Hajibandeh S, Hajibandeh S, Kennedy-Dalby A, Rehman S, Zadeh RA. Purse-string skin closure versus linear skin closure techniques in stoma closure: a comprehensive meta-analysis with trial sequential analysis of randomised trials. Int J Colorectal Dis. 2018 Oct 3;33(10):1319–32.

120. Clavien PA, Puhan MA, Measuring and achieving the best possible outcomes in surgery. Br J Surg. 2017;104(9):1121–2.
121. Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. Vol. 21, Inflammatory Bowel Diseases. 2015. p. 2658–72.

122. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010 Feb 15;31(4):486–92.

123. El-Hussuna A, Krag A, Olaion G, Bendisen F, Gluud LL. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn’s disease: a systematic review. Dis Colon Rectum. 2013 Dec;56(12):1423–33.

124. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 2015 Jan;21(1):79–92.

125. Iesalnieks I, Kilger A, Glass H, Müller-Wille R, Klebl F, Ott C, et al. Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome. Int J Colorectal Dis. 2008 Dec;23(12):1167–74.

126. Sampietro GM, Corsi F, MacOni G, Ardizzzone S, Frontali A, Corona A, et al. Prospective Study of Long-Term Results and Prognostic Factors After Conservative Surgery for Small Bowel Crohn’s Disease. Clin Gastroenterol Hepatol. 2009;7(2):183–91.

127. Canedo J, Pinto RA, Regadas S, Regadas FSP, Rosen L, Wexner SD. Laparoscopic surgery for inflammatory bowel disease: does weight matter? Surg Endosc. 2010 Jun;24(6):1274–9.

128. Holubar SD, Dozois EJ, Privitera A, Pemberton JH, Cima RR, Larson DW. Minimally invasive colectomy for Crohn’s colitis: A single institution experience. Inflamm Bowel Dis. 2010;16(11):1940–6.

129. De Silva S, Ma C, Proulx MC, Crespin M, Kaplan BS, Hubbard J, et al. Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2011;9(11):972–80.

130. Mascarenhas C, Nunoo R, Asgeirsson T, Rivera R, Kim D, Hoedema R, et al. Outcomes of ileocolic resection and right hemicolectomies for Crohn’s patients in comparison with non-Crohn’s patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications. Am J Surg. 2012;203(3):375–8.

131. Riss S, Bittermann C, Schwameis K, Kristo I, Mittlböck M, Herbst F, et al. Determinants for postoperative complications after laparoscopic intestinal resection for Crohn’s disease. Surg Endosc. 2012;26(4):933–8.

132. Tzivanakis a., Singh JC, Guy RJ, Travis SPL, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in crohn’s disease surgery. Dis Colon Rectum. 2012;55:558–62.

133. Bellolio F, Cohen Z, Macrae HM, O’Connor BI, Huang H, Victor JC, et al. Outcomes following surgery for perforating Crohn’s disease. Br J Surg. 2013;100(10):1344–8.

134. Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Color Dis. 2013;15(9):1123–9.
135. Bartels SAL, Gardenbroek TJ, Bos L, Ponsioen CY, D’Haens GRAM, Tanis PJ, et al. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. Color Dis. 2013;15(11):1392–8.

136. Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis a cohort study. Ann Intern Med. 2015;163(4):262–70.

137. Hicks CW, Hodin RA, Bordeianou L. Semi-urgent surgery in hospitalized patients with severe ulcerative colitis does not increase overall J-pouch complications. Am J Surg. 2014;207(2):281–7.

138. Morar PS, Hodgkinson JD, Thalayasingam S, Koysombat K, Purcell M, Hart AL, et al. Determining predictors for intra-abdominal septic complications following ileocolonic resection for Crohn’s disease—considerations in pre-operative and peri-operative optimisation techniques to improve outcome. J Crohn’s Colitis. 2015;9(6):483–91.

139. Zuo L, Li Y, Wang H, Zhu W, Zhang W, Gong J, et al. A practical predictive index for intra-abdominal septic complications after primary anastomosis for Crohn’s disease: Change in C-reactive protein level before surgery. Dis Colon Rectum. 2015;58(8):775–81.

140. Li Y, Stocchi L, Cherla D, Liu X, Remzi FH. Association of preoperative narcotic use with postoperative complications and prolonged length of hospital stay in patients with Crohn disease. JAMA Surg. 2016 Aug 1;151(8):726–34.

141. Germain A, Guéant RM, Chamaillard M, Allen PB, Bresler L, Guéant JL, et al. NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn’s disease: A genetic association study. Surg (United States). 2016;160(1):74–80.

142. Yamamoto T, Spinelli A, Suzuki Y, Saad-Hossne R, Teixeira FV, de Albuquerque IC, et al. Risk factors for complications after ileocolonic resection for Crohn’s disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United Eur Gastroenterol J. 2016;4(6):784–93.

143. Sahami S, Bartels SAL, D’Hoore A, Fadok TY, Tanis PJ, Lindeboom R, et al. A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch–Anal Anastomosis for Inflammatory Bowel Disease. J Crohn’s Colitis. 2016 Jul;10(7):773–8.

144. Guo K, Ren J, Li G, Hu Q, Wu X, Wang Z, et al. Risk factors of surgical site infections in patients with Crohn’s disease complicated with gastrointestinal fistula. Int J Colorectal Dis. 2017;32(5):635–43.

145. Diederik K, Sahami SS, Tabbers MM, Benninga MA, Kindermann A, Tanis PJ, et al. Outcome after restorative proctocolectomy and ileal pouch–anal anastomosis in children and adults. Br J Surg. 2017;104(12):1640–7.

146. Heimann TM, Swaminathan S, Greenstein AJ, Steinhagen RM. Incidence and Factors Correlating with Incisional Hernia Following Open Bowel Resection in Patients with Inflammatory Bowel Disease: A Review of 1000 Patients. Ann Surg. 2018;267(3):532–6.

147. Huang W, Tang Y, Nong L, Sun Y. Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn’s disease: A meta-analysis of observational studies. J
148. Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis. 2011 Jul;17(7):1610–9.
Figure 1 Graphical representation of the theoretical in vivo half-lives of biologic agents used to treat CUC. Note this graph assumes first order elimination pharmacokinetics. With permission from Stefan Holubar.
Table 1
Clinical studies about type of pre-operative biological treatment in patients with Crohn’s disease. The time interval between last administered dose of biological treatment and surgery varied among the studies.

| Author/publication’s year | Cohort/treated | Type of biological treatment | Weeks before surgery |
|---------------------------|----------------|-------------------------------|----------------------|
| Observational retrospective studies | | | |
| 1 | Tay et al 2003 | 100/22 | IFX | 8 |
| 2 | Colombel et al 2004 | 270/52 | IFX | 8* |
| 3 | Marchal et al 2004 | 79/40 | IFX | 12** (8,4 and less than 4 weeks) |
| 4 | Appau et al 2008 | 389/60 | IFX | 12 |
| 5 | Indar et al 2009 | 112/17 | Anti-TNF | 8 |
| 6 | Nasir et al 2010 | 370/119 | IFX, ADA, CZM | 8* |
| 7 | Kasparek et al 2011 | 94/48 | IFX | 12 |
| 8 | Canedo et al 2011 | 225/65 | IFX | 8 |
| 9 | Regueiro et al 2011 | 24/11 | IFX | 2-4 weeks after surgery*** |
| 10 | El-Hussuna et al 2012 | 417/32 | IFX, ADA, CZM | 12 |
| 11 | White et al 2012 | 338/59 | IFX, ADA, CZM | 12 |
| 12 | Myrelid et al 2013 | 298/111 | IFX, ADA | 8 |
| 13 | Serradori et al 2013 | 217/42 | Anti-TNF | 12 (and 8 weeks) |
| 14 | Syed et al 2013 | 325/150 | Anti-TNF | 8 |
| 15 | Uchino et al 2013 | 405/79 | IFX | 12 |
| 16 | Bafford et al 2013 | 196/35 | Anti-TNF | 12 |
| 17 | Kotze et al 2016 | 123/71 | IFX, ADA | 8 |
|   | Authors                                      | Follow up | Therapies                  | Duration |
|---|---------------------------------------------|-----------|----------------------------|----------|
| 18| Shim et al 2016                            | 60/60     | Anti-TNF, UST              | Up to 72 |
| 19| Zimmerman et al 2016                       | 123/24n   | IFX                        | 12 (8 and 4 weeks) |
| 20| Kotze et al 2017                           | 123/71    | ADA                        | 2        |
| 21| Jouvin et al 2018                          | 360/58    | IFX, ADA, CZM              | 8        |
| 22| Lightner et al 2018                        | 213/213 (169 anti-TNF-α) | Anti-TNF-α and UST | 12        |

**Prospective studies**

|   | Authors                                      | Follow up | Therapies                  | Duration |
|---|---------------------------------------------|-----------|----------------------------|----------|
| 23| Brouquet et al 2016                         | 592/340   | IFX, ADA, VDZ, other Anti-TNF | 12       |
| 24| Fumery et al 2016                           | 209/93    | IFX, ADA                   | 12 (and 4 weeks) |

**Nation-wide database study**

|   | Authors                                      | Follow up | Therapies                  | Duration |
|---|---------------------------------------------|-----------|----------------------------|----------|
| 25| Nørgård et al 2013                          | 2293/214  | IFX, ADA, CZM              | 12 (2 & 4 weeks) |

*and 4 weeks after surgery
**Nine patients received anti-TNF-α more than 12 weeks prior to surgery
***Data was collected from a randomised clinical trial to investigate postoperative recurrence of CD

Paediatric patients

IFX: Infliximab, ADA: Adalimumab, CZM: Certolizumab, UST: Ustekinumab, VDZ: Vedolizumab, Anti-TNF: Anti-tumour necrosis factor agents
Table 2
Clinical studies about type of pre-operative biological treatment in patients with Crohn’s disease, Ulcerative Colitis and indeterminate colitis (mixed population studies)

| Author/publication’s year | Cohort/treated | Type of biological treatment | Weeks before surgery |
|---------------------------|----------------|------------------------------|----------------------|
| **Observational retrospective studies** | | | |
| 1 | Kunitake et al 2008 | 413/101 | IFX | 12 |
| 2 | Regadas et al 2010 | 249/28 | IFX | 8 |
| 3 | Rizzo et al 2011 | 114/54 | Anti-TNF | 12 (and 4 weeks) |
| 4 | Krane et al 2013 | 518/142 | IFX | 12 |
| 5 | Waterman et al 2013 | 282/73 | IFX, ADA | 25 |
| 6 | Lau et al 2015 | 217/143 | IFX, ADA, CZM | Not specified* |
| 7 | Alsaleh et al 2016 | 47/47 | IFX | 12 |
| 8 | Lightner et al 2016 | 392/220 | VDZ | 12 |
| 9 | Shwaartz et al 2016 | 282/73 | IFX, ADA, CZM | 8 |
| 10 | Yamada et al 2017 | 443/193 | IFX, ADA, VDZ | 4 |
| **Prospective studies** | | | |
| 11 | El-Hussuna et al 2018 | 46/18 | IFX, ADA, CZM | 12 |

IFX: Infliximab, ADA: Adalimumab, CZM: Cemizia, VDZ: Vedolizumab
Anti-TNF: Anti-tumour necrosis factor agents

*About 65% of patients in this cohort received Anti-TNF-α therapy before surgery.
Table 3
Clinical studies about type of pre-operative biological treatment in patients with Ulcerative Colitis

| Author/publication’s year | Cohort/treated 11965/2181 | Type of biological treatment | Weeks before surgery |
|---------------------------|---------------------------|-----------------------------|-----------------------|
| **Observational retrospective studies** | | | |
| 1  Selvasekar\(^{53}\) et al 2007 | 301/47 | IFX | 8* |
| 2  Schluender\(^{44}\) et al 2007 | 151/17 | IFX | Up to 54 |
| 3  Mor\(^{51}\) et al 2008 | 523/85 | IFX | Up to 37 |
| 4  Ferrante\(^{52}\) et al 2009 | 141/22 | IFX | Up 12 |
| 5  Coquet-Reinier\(^{53}\) et al 2010 | 26/13 | IFX | Up to 23 |
| 6  Gainsbury\(^{54}\) et al 2011 | 81/29 | IFX | 12 |
| 7  Bregnbak\(^{55}\) et al 2012 | 71/20 | IFX | 12 |
| 8  Kennedy\(^{56}\) et al 2012 | 38/11 | IFX | 8 |
| 9  Uchino\(^{57}\) et al 2013 | 196/22 | IFX | 12 |
| 10 Eshuis\(^{58}\) et al 2013 | 72/38 | IFX | Up to 32 |
| 11 Gu\(^{59}\) et al 2013 | 181/25 | IFX, ADA, CZM | 12 |
| 12 Nelson\(^{60}\) et al 2014 | 78/28 | IFX | 1 |
| 13 Zittan\(^{57}\) et al 2016 | 562/196 | Anti-TNF | Up to 24 |
| 14 Kulaylat\(^{61}\) et al 2017 | 2476/650 | IFX, ADA, CZM | 12 |
| 15 Lightner\(^{62}\) et al 2017 | 150/150 | VDZ | 12 |
| 16 Ferrante\(^{63}\) et al 2017 | 170/94 | VDZ, Anti-TNF | 8-16 |
| **Nation-wide database study** | | | |
| 17 Nørgård\(^{57}\) et al 2013 | 1226/199 | Anti-TNF | 12 |
|   | Ward et al 2017 | 6225/753 | Anti-TNF | 12 (and 4 weeks) |
|---|----------------|----------|----------|------------------|

IFX: Infliximab, ADA: Adalimumab, CZM: Cemizia, VDZ: Vedolizumab Anti-TNF: Anti-tumour necrosis factor agents

* Only 49% of patients in the study cohort

π Paediatric age cohort
Table 4
Meta-analyses and systematic reviews that investigated the effect of biological treatment on postoperative outcome in patients with inflammatory bowel disease. It shows 12 reviews about CD, 9 about mixed population and only 3 about UC.

| Author/publication’s year | Disease       | Primary outcome                        |
|---------------------------|---------------|----------------------------------------|
| **Systematic/narrative reviews** |               |                                        |
| 1 Subramanian et al 2006  | CD & UC       | Postoperative complications             |
| 2 Ali et al 2012          | CD & UC       | Postoperative complications             |
| 3 El-Hussuna et al 2014   | CD            | Postoperative complications             |
| 4 Papaconstantinou et al 2014 | CD            | Postoperative complications             |
| 5 Saab et al 2015         | CD            | Postoperative complications             |
| 6 Holubar et al 2015      | CD & UC       | Overall/infectious complications        |
| 7 Alexakis et al 2015     | UC            | Colectomy and hospitalization rates     |
| 8 Chang et al 2015        | CD            | Surgical complications                  |
| 9 Kotze et al 2017        | CD            | Postoperative complications             |
| 10 Engel et al 2017       | CD & UC       | Postoperative complications             |
| **Meta-analyses**         |               |                                        |
| 1 Yang et al 2009         | UC            | Postoperative complications             |
| 2 Ehteshami-Afshar et al 2011 | CD & UC       | Colectomy and hospitalization rates     |
| 3 Kopylov et al 2012      | CD            | Colectomy and hospitalization rates     |
| 4 El-Hussuna et al 2013   | CD            | Anastomotic complications               |
| 5 Billiou et al 2013      | CD & UC       | Postoperative complications             |
| 6 Narula et al 2013       | CD & UC       | Postoperative complications             |
| 7 Rosenfeld et al 2013    | CD            | Postoperative complications             |
|   | Authors       | Year | Design | Type               |
|---|--------------|------|--------|--------------------|
| 8 | Yang et al 2014 | CD   |        | Postoperative complications |
| 9 | Ahmed Ali et al 2014 | CD   |        | Overall/infectious complications |
| 10 | Selvaggi et al 2015 | UC   |        | Pouch-related postoperative complications |
| 11 | Waterland et al 2016 | CD   |        | Infectious complications |
| 12 | Law et al 2018 | CD & UC | | Overall/infectious complications |
| 13 | Xu et al 2018 | CD   |        | Postoperative complications |
| 14 | Yung et al 2018 | CD & UC | | Postoperative complications |
Table 5
Clinical studies about risk factors for unfavorable postoperative outcome in patients with Crohn’s disease and Ulcerative colitis. In these studies, biological treatment was analysed as part of the risk factors in multivariate analysis.

| Author/publication’s year | Disease | Cohort/treated | Type of biological treatment | Weeks before surgery |
|---------------------------|---------|----------------|-----------------------------|----------------------|
| Iesalnieks et al 2008     | CD      | 282/4          | IFX                         | 8                    |
| Sampietro et al 2009      | CD      | 393/13         | Biological agents (not specified) | Not specified |
| Canedo et al 2010         | CD & UC | 213/61         | IFX, ADA                    | 8                    |
| Holubar et al 2010        | CD      | 92/32          | Biological agents (not specified) | Not specified |
| De Silva et al 2011       | UC      | 666/58         | IFX                         | Not specified |
| Mascarenhas et al 2012    | CD      | 93/19          | IFX, ADA and others (not specified) | 12 |
| Riss et al 2012           | CD      | 182/3          | IFX                         | 1                    |
| Tzivanakis et al 2012     | CD      | 207/not stated | IFX                         | Not specified |
| Bellolio et al 2013       | CD      | 434/42         | Biological agents (not specified) | Not specified |
| Gu et al 2013             | UC      | 204/73         | Anti-TNF-α (not specified)  | Not specified |
| Bartels et al 2013        | UC      | 71/16          | Anti-TNF-α (not specified)  | Not specified |
| Bewtra et al 2013         | UC      | 830/65         | IFX                         | Not specified |
| Hicks et al 2014          | UC      | 179/43         | IFX                         | Not specified |
| Morar et al 2015          | CD      | 142/4          | IFX, ADA                    | 4                    |
| Zuo et al 2015            | CD      | 344/8          | IFX                         | Not specified |
|   | Author(s) Reference | Disease | Number of Patients | Treatment | Study Design |
|---|---------------------|---------|--------------------|-----------|--------------|
| 16 | Feuerstein et al 2015 | UC | 209/24 | Anti-TNF-α (not specified) | Not specified |
| 17 | Li et al 2016 | CD | 1461/190 | Biological agents (not specified) | Not specified |
| 18 | Germain et al 2016 | CD | 137/13 | Anti-TNF-α (not specified) | 8 |
| 19 | Yamamoto et al 2016 | CD | 231/79 | IFX, ADA | 8 |
| 20 | Sahami et al 2016 | UC | 640/51 | Anti-TNF-α (not specified) | 12 |
| 21 | Guo et al 2017 | CD | 118/11 | Anti-TNF-α (not specified) | 24 |
| 22 | Collaborative 2017 | CD | 375/82 | IFX, ADA, CZM and others (not specified) | 12 |
| 23 | Diederen et al 2017 | UC | 422/14 | Anti-TNF-α (not specified) | 12 |
| 24 | Galata et al 2018 | CD | 305/72 | IFX, ADA, Golimumab, Vedozulimab and others | 4 |
| 25 | Heimann et al 2018 | CD & UC | 1000/71 | Biological agents (not specified) | 6 |

Reviews

|   | Author(s) Reference | Disease | Number of Patients | Treatment | Study Design |
|---|---------------------|---------|--------------------|-----------|--------------|
| 26 | Huang et al 2015 | CD | 3807/1833 | Biological agents (not specified) | Not specified |
| 27 | Beddy et al 2011 | CD & UC | Not stated | Biological agents (not specified) | Not specified |

IFX: Infliximab, ADA: Adalimumab, CZM: Cemizia, Anti-TNF-α: anti-tumour necrosis factor alpha agents